var data={"title":"Dexamethasone (ophthalmic): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexamethasone (ophthalmic): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388153?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexamethasone-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexamethasone (ophthalmic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=dexamethasone-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexamethasone (ophthalmic): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015642\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Maxidex;</li>\n      <li>Ozurdex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015643\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Diodex;</li>\n      <li>Maxidex;</li>\n      <li>Ozurdex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016748\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-inflammatory Agent, Ophthalmic;</li>\n      <li>\n        Corticosteroid, Ophthalmic;</li>\n      <li>\n        Corticosteroid, Otic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015738\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ocular inflammation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment [Canadian product]: Apply thin coating of ointment into conjunctival sac 3 to 4 times/day; when clinically indicated, may reduce application frequency gradually to once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Instill 1 to 2 drops into conjunctival sac every hour during the day and every other hour during the night; gradually reduce dose to 1 drop every 4 hours, then to 3 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suspension: Instill 1 to 2 drops into conjunctival sac up to 4 to 6 times/day; may use hourly in severe disease; taper prior to discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otic inflammation:</b> Otic: Solution: Initial: Instill 3 to 4 drops into the aural canal 2 to 3 times a day; reduce dose gradually once a favorable response is obtained. Alternately, may pack the aural canal with a gauze wick saturated with the solution; remove from the ear after 12 to 24 hours. Repeat as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic macular edema (pseudophakic or phakic patients scheduled for cataract surgery) or macular edema (following BRVO or CRVO):</b> Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Noninfective uveitis:</b> Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50782593\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dexamethasone-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexamethasone (ophthalmic): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ocular inflammation:</b> Infants, Children, and Adolescents: Ophthalmic: Suspension: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015739\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Solution/suspension: Use cautiously in the elderly in the smallest possible dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15827037\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15827038\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016302\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Implant, Intravitreal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ozurdex: 0.7 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxidex: 0.1% (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015645\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46306997\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment, Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maxidex: 0.1% (3.5 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51109366\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Dexycu (dexamethasone intraocular suspension): FDA approved February 2018; anticipated availability is currently unknown. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016290\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic ointment [Canadian product]: Gently pull down under eye to form pocket between eyeball and lower eyelid, then apply ointment into pocket; patient should look down prior to closing eye. Do not touch tip of dropper to eye(s) or any other surface.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic solution, suspension: Remove soft contact lenses prior to using solutions containing benzalkonium chloride. Do not touch tip of container to eye. Shake suspension well prior to use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic solution may also be administered otically. Prior to use, clean the aural canal thoroughly and sponge dry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic implant (intravitreal injection): Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Administer adequate anesthesia and a broad-spectrum bactericidal to the periocular skin, eyelid, and ocular surfaces prior to injection. Refer to manufacturer's prescribing information for administration technique. If administration is required in the second eye, a new applicator should be used and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8083884\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Management of steroid-responsive inflammatory conditions such as allergic conjunctivitis, iritis, or cyclitis; symptomatic treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The ophthalmic solution is also indicated for otic use to treat steroid-responsive inflammatory conditions of the external auditory meatus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic intravitreal implant (Ozurdex): Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); treatment of noninfective uveitis affecting the posterior segment of the eye; treatment of diabetic macular edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015641\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexamethasone may be confused with desoximetasone, dextroamphetamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxidex may be confused with Maxzide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10118944\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular implant/injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (implant: 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Cataract (implant: 5% to 68%; incidence increases in patients requiring a second injection), increased intraocular pressure (implant: 25%, &ge;10 mm Hg: 28%, &ge;30 mm Hg: 15%; injection: 5% to 15%), conjunctival hemorrhage (implant: 22% to 23%), corneal edema (injection: 5% to 15%; implant: &lt;1%), iritis (injection: 5% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Aneurysm (implant: 3%; retinal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Foreign body sensation of eye (&le;5%), headache (implant: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Decreased visual acuity (1% to 9%), eye pain (&le;8%), conjunctival hyperemia (implant: 7%), conjunctivitis (implant: &le;6%), corneal erosion (&le;5%), xerophthalmia (&le;5%), conjunctival edema (implant: 5%), ocular hypertension (implant: 5%), blepharitis (injection: 1% to 5%), blurred vision (injection: 1% to 5%), cystoid macular edema (injection: 1% to 5%), ophthalmic inflammation (injection: 1% to 5%), photophobia (injection: 1% to 5%), posterior capsule opacification (injection: 1% to 5%), vitreous detachment (1% to 5%), vitreous opacity (1% to 5%), anterior chamber inflammation (implant: 2%), retinal hole without detachment (implant: 2%), blepharoptosis (implant: &le;2%), keratitis (implant: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (implant: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Ophthalmic: Glaucoma (injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Ophthalmic solution/suspension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Burning sensation of eyes, cataract, decreased visual acuity, eye perforation, filtering blebs, glaucoma (with optic nerve damage), secondary ocular infection, stinging of eyes, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% postmarketing, and/or case reports: Blurred vision, conjunctivitis, crusting of eyelid, decreased intraocular pressure (associated with vitreous leakage from injection), endophthalmitis, eye pain, eye pruritus, foreign body sensation of eye, increased lacrimation, keratitis, mydriasis, ocular hyperemia, photophobia, retinal detachment, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015654\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to dexamethasone or any component of the formulation or product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension/solution, ointment [Canadian product]: Viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial or fungal infection of the eye; acute, untreated bacterial infections of the eye; the solution should also not be used for otic indications if perforation of a drum membrane is present</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravitreal implant: Glaucoma with cup to disc ratios of greater than 0.8; active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases; use in patients with a posterior lens capsule that is torn or ruptured</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Anterior chamber intraocular lens (ACIOL) and rupture of posterior lens capsule; aphakic eyes with rupture of the posterior lens capsule</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8083886\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use may increase the hazard of secondary ocular infections. May mask infection or enhance existing infection. The possibility of persistent corneal fungal infection should be considered after prolonged use. Corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex; reactivation of viral infection may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Avoid prolonged use, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Hypotony of the eyes have also been reported with the implant, some of which were serious. Monitor intraocular pressure if topical ophthalmic products are used for 10 days or longer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Perforations may occur in diseases which cause thinning of the cornea or sclera.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Ophthalmic solution and suspension contain benzalkonium chloride which may be absorbed by contact lenses; contact lens should not be worn during treatment of ophthalmic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intravitreal implant: Endophthalmitis, ocular inflammation, intraocular pressure elevations and retinal detachments may occur with intravitreal injection. Intraocular pressure elevations peak ~8 weeks following injection; prolonged monitoring of intraocular pressure may be required. A risk of implant migration into the anterior chamber may be present if the posterior capsule of the lens is absent or torn. Temporary blurring may occur following intravitreal injections; patients should not drive until this resolves. Administer adequate anesthesia and a broad-spectrum microbicide prior to procedure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299141\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015662\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9099&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dexamethasone (Ophthalmic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8083888\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9890216\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies following use of ophthalmic dexamethasone. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9890218\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Although it is not known if detectable concentrations are found in breast milk following application of ophthalmic dexamethasone, the manufacturer recommends caution be used if administered to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016292\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic solution/suspension: Intraocular pressure (with use &gt;10 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic implant (intravitreal injection): Following injection, monitor for increased intraocular pressure and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, biomicroscopy between 2-7 days after injection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10893630\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10118950\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Ocular implant: BRVO/CRVO: Improvement observed in 20% to 30% of patients within first 2 months following intravitreal injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of effect: Ocular implant: BRVO/CRVO: ~1 to 3 months (following onset of improvement)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Ocular implant: Systemic levels negligible in majority of patients (&le;50 pg/mL) &le;90 days following implant, highest systemic concentration observed: 102 pg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016304\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Implant</b> (Ozurdex Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.7 mg (1): $1,599.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexamethasone Sodium Phosphate Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 mL): $64.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Maxidex Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (5 mL): $90.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961969\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acilot (LK);</li>\n      <li>Apidex (BD);</li>\n      <li>Betam-Ophtal (ID);</li>\n      <li>Decadron (CO, EC);</li>\n      <li>Dexa-Sine (BE);</li>\n      <li>Dexa-Sine SE (NO);</li>\n      <li>Dexacip (LK);</li>\n      <li>Dexafree (CH, ES, FR, GB, IE, PL, PT);</li>\n      <li>Dexagel (TH);</li>\n      <li>Dexason (BD);</li>\n      <li>Dexomet (LK);</li>\n      <li>Dian Shu (CN);</li>\n      <li>Dropodex (IE, MT);</li>\n      <li>Isopto-Dex (DE);</li>\n      <li>Isopto-Maxidex (AR, CO, NO, PY);</li>\n      <li>Maksydtks (UA);</li>\n      <li>Maradex (VE);</li>\n      <li>Maxidex (AE, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CY, CZ, DK, EC, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HN, HR, HU, IE, IL, IQ, IR, IS, JO, KE, KR, KW, LB, LK, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NZ, OM, PE, PH, PK, QA, RO, RU, SA, SC, SD, SE, SG, SI, SL, SN, SY, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Nexadron Oftal (AR);</li>\n      <li>Oftan (UA);</li>\n      <li>Oftan Dexa (EE, FI);</li>\n      <li>Opnol (SE);</li>\n      <li>Orbidex (LK);</li>\n      <li>Ozurdeks (UA);</li>\n      <li>Ozurdex (AE, AT, BE, CH, CO, CZ, DE, DK, EE, FR, GB, HK, HR, IE, IL, IN, IS, JO, KR, LB, LK, LT, LU, LV, MT, MY, NL, NO, PH, PL, PT, RO, SE, SG, SI, SK, TH, VN);</li>\n      <li>Santeson (PH);</li>\n      <li>Spersadex (CH, DE, HK, LU, NO, ZA);</li>\n      <li>Sterodex (IL);</li>\n      <li>Steron (BD);</li>\n      <li>Thilodexine (GR);</li>\n      <li>Visumetazone (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Lowder C, Belfort R Jr, Lightman S, et al, &quot;Ozurdex HURON Study Group. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis,&quot; <i>Arch Ophthalmol</i>, 2011, 129(5):545-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexamethasone-ophthalmic-drug-information/abstract-text/21220619/pubmed\" target=\"_blank\" id=\"21220619\">21220619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxidex (dexamethasone) [prescribing information]. Fort Worth, Texas: Alcon Laboratories Inc; received November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxidex (dexamethasone) [product monograph]. Mississauga, Ontario, Canada: Alcon Canada Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozurdex (dexamethasone) [prescribing information]. Irvine, CA: Allergan Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozurdex (dexamethasone) [product monograph]. Markham, Ontario, Canada: Allergan Inc; April 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9099 Version 136.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8015642\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8015643\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8016748\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8015738\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50782593\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8015739\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15827037\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15827038\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8016302\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8015645\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46306997\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51109366\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8016290\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8083884\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8015641\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10118944\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8015654\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8083886\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299141\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8015662\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8083888\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9890216\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9890218\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8016292\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10893630\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10118950\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8016304\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961969\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9099|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexamethasone-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Dexamethasone (ophthalmic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=dexamethasone-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">Dexamethasone (ophthalmic): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}